Estring

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more

Treatment

5 FDA approvals

20 Active Studies for Estring

What is Estring

Estradiol

The Generic name of this drug

Treatment Summary

Estradiol is a hormone that is naturally found in women and is used to treat conditions caused by low estrogen levels, such as hot flashes and vaginal dryness. It comes in several forms, including tablets, injections, vaginal rings, patches, sprays, gels, and creams. Ethinyl estradiol is a synthetic form of estradiol that is commonly used in oral contraceptives. It is more effective when taken orally than estradiol because it has a higher bioavailability and is more resistant to being broken down in the body.

Estraderm

is the brand name

image of different drug pills on a surface

Estring Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Estraderm

Estradiol

1986

373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Hormonal Contraception and Breast Cancer .

Hormonal Contraception

Used to treat Hormonal Contraception therapy in combination with Levonorgestrel

Breast Cancer

Birth Control

Used to treat Contraception in combination with Levonorgestrel

Palliative Treatment

Breast Cancer

Effectiveness

How Estring Affects Patients

Estradiol is a hormone that helps to reduce hot flashes, vaginal dryness, and pain during sex. It can also increase bone density and have positive effects on the body's cholesterol levels. Estradiol can also increase certain proteins in the liver, such as sex hormone binding globulin and thyroid-binding globulin, and suppress the formation of follicle-stimulating hormone. However, it can also increase the risk of cardiovascular disease, deep vein thrombosis, and stroke, so it should be avoided in people at high risk for these conditions. Additionally, estradiol can cause a hyper-coagul

How Estring works in the body

Estrogen is found in many parts of the body and is produced mainly by the ovarian follicles in women who are still going through their reproductive period. After menopause, most estrogen is made by transforming androstenedione (from the adrenal cortex) to estrone. Estrogen works by binding to receptors in the body, including ERα and ERβ, which then enter the nucleus of the target cell and activate certain genes. This process causes the body to produce proteins that express the effects of estradiol. Estrogen has a range of effects, including reducing hot flashes, chills, mood swings, and sleep problems in

When to interrupt dosage

The encouraged measure of Estring is subject to the determined condition, for example, Premature Menopause, Pharmaceutical Preparations and Postmenopause. The amount of dosage is contingent on the technique of administration enumerated in the table beneath.

Condition

Dosage

Administration

Hot Flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Balanitis Xerotica Obliterans

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Hot flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Palliative Treatment

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Breast

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Amenorrhea

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Therapeutic procedure

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Postmenopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Breast Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Vasomotor System

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Prostate Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Pharmaceutical Preparations

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Hormone Replacement Therapy

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

female castration

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

estradiol

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Premature Menopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Atrophic

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Hypogonadism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Osteoporosis

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

hypoestrogenism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Ring - Vaginal, Vaginal, Ring, Spray - Transdermal, Transdermal, Spray, Patch, extended release, Patch, extended release - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Patch, Patch - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Gel, metered - Topical, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable

Warnings

Estring has eighteen contraindications. It should not be utilized in combination with the ailments presented in the following table.

Estring Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Angioedema

Do Not Combine

Venous Thrombosis

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Liver Dysfunction

Do Not Combine

Breast

Do Not Combine

suspected pregnancy

Do Not Combine

Breast Cancer

Do Not Combine

Pulmonary Embolism

Do Not Combine

Angioedema

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Thromboembolism

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Pulmonary Embolism

Do Not Combine

Thromboembolism

Do Not Combine

Thrombophilia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Estradiol may interact with Pulse Frequency

There are 20 known major drug interactions with Estring.

Common Estring Drug Interactions

Drug Name

Risk Level

Description

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Estradiol.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Estradiol.

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Estradiol.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Estradiol.

Estring Toxicity & Overdose Risk

The amount of estradiol that is considered safe for rats to consume orally over a 90-day period is 0.003mg/kg/day. The highest dose of estradiol that has been found to be toxic to humans is 21mg/kg/21 days. Symptoms of estradiol overdose may include nausea, vomiting, abdominal pain, breast tenderness, blood clots, or vaginal bleeding. If an overdose occurs, it is recommended to cease using estradiol and provide supportive care.

Estring Novel Uses: Which Conditions Have a Clinical Trial Featuring Estring?

Currently, 867 clinical trials are assessing the potential of Estring to address Osteoporosis, Absent Menses for 6 Months or More and Urogenital Atrophy.

Condition

Clinical Trials

Trial Phases

Hysterectomy

6 Actively Recruiting

Phase 4, Phase 3, Not Applicable

Breast Cancer

19 Actively Recruiting

Phase 2, Not Applicable

estradiol

0 Actively Recruiting

Birth Control

20 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Postmenopause

5 Actively Recruiting

Not Applicable

Metastatic Breast Cancer

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

moderate to severe symptoms

0 Actively Recruiting

Balanitis Xerotica Obliterans

0 Actively Recruiting

Amenorrhea

1 Actively Recruiting

Phase 2

Osteoporosis

26 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Prostate Cancer

72 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1

Breast

0 Actively Recruiting

Urogenital atrophy

0 Actively Recruiting

Low Testosterone

4 Actively Recruiting

Phase 2, Phase 1, Phase 4

Vasomotor System

0 Actively Recruiting

Atrophic Vaginitis

1 Actively Recruiting

Not Applicable

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Hormone Replacement Therapy

0 Actively Recruiting

Estring Reviews: What are patients saying about Estring?

5

Patient Review

5/5/2020

Estring for Vaginal Inflammation due to Loss of Hormone Stimulation

I've been using this for three months now and the only possible side effect is that my vision has gotten worse. I'm 59, so it might just be age. However, I can tell a difference in my vaginal tone and lubrication.

5

Patient Review

12/15/2020

Estring for Postmenopausal Urethral Atrophy

I bled for two days after sex, even though I had been using the vaginal cream for a year. But then I tried Estring and felt normal again within a month. The only downside is that now I can't afford it because I'm on Medicare. It's really sad that those who need it the most can't use the coupon.

5

Patient Review

5/20/2021

Estring for Postmenopausal Urethral Atrophy

Estring is great! Easy to use and comfortable. No mess! BUT don't waste your time until you know if your insurance covers it!

5

Patient Review

2/16/2022

Estring for Vaginal Inflammation due to Loss of Hormone Stimulation

I was so pleased with E String, and it worked perfectly for me for over two years. But then my consultant said I needed to take a break from it, and my GP couldn't tell me when or if I could use it again. Now my symptoms have returned and I'm using Vagirux instead, but I really want to go back on E String.

5

Patient Review

7/28/2022

Estring for Postmenopausal Urethral Atrophy

So far, I've been really pleased. It's easy to insert and there's no discomfort. I'm only a week in, but fingers crossed it will help with the pain and dryness I experience during sex.

4.7

Patient Review

5/24/2021

Estring for Postmenopausal Urethral Atrophy

I love this product, but I'm infuriated by how much more expensive it is for women than men's medication. It's not fair, and it puts a huge financial burden on already disadvantaged people.

4.3

Patient Review

4/6/2021

Estring for Postmenopausal Urethral Atrophy

The ring was a bit tough to remove, but I'm glad I stuck it out. It would have been helpful to know what the ideal feeling should be when removing the ring.

3.7

Patient Review

6/23/2020

Estring for Postmenopausal Urethral Atrophy

I love the Estring BUT why is its so hard to remove. I cannot do it by myself. Manufacturer should provide a device to remove it....I had a kind of "hook" to use when I had a diaphragm years ago.

3.3

Patient Review

11/15/2020

Estring for Postmenopausal Urethral Atrophy

The estring helped with my vaginal dryness and atrophy, as well as the pain I experienced during sex. However, there was a lot of discharge while using it. After eight months, I developed a bacterial infection which my doctor said was likely due to the estring. So, after finishing antibiotics, I'll be trying an estrogen cream instead.

3

Patient Review

9/13/2021

Estring for Postmenopausal Urethral Atrophy

I've used this for the past three years, but I can't seem to remove it on my own. My husband has to help me take it out. Additionally, I think it's caused me to gain weight around my middle.

1

Patient Review

2/26/2022

Estring for Postmenopausal Urethral Atrophy

I wasn't able to use this product because the ring is too large. Additionally, the contour makes it very difficult and uncomfortable to insert.

1

Patient Review

8/15/2022

Estring for Vaginal Inflammation due to Loss of Hormone Stimulation

The ring is very hard and big! I had a hard time getting it in and even worse trying to get it out. I used it for two weeks but got a bacterial infection so I stopped using it. The side effects weren't worth it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about estring

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the estring cause weight gain?

"Studies show that there is no link between estrogen and weight gain. The estrogen ring is not a factor in weight gain. Common factors that contribute to weight gain are age and lifestyle."

Answered by AI

What is estring used for?

"Estring is a soft, flexible ring used after menopause that continuously releases an estrogen over 3 months to treat menopausal changes in and around the vagina. It is important to keep in mind that estrogen therapies such as Estring should be used only as long as they are needed."

Answered by AI

Is estring considered HRT?

"There are two main types of HRT vaginal rings: Estring (estradiol) and Femring (estradiol acetate)."

Answered by AI

How long do you leave estring in?

"After 90 days of continued use, you and your doctor should talk about whether you still need treatment with Estring."

Answered by AI

Clinical Trials for Estring

Image of University Health Network - Princess Margaret Cancer Center in Toronto, Canada.

Tamoxifen for Testosterone Recovery in Prostate Cancer

18+
Male
Toronto, Canada

Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. The hypogonadal state has significant psychosocial and physical side effects. Therefore, limiting ADT effect's duration beyond the prescribed castration period is very compelling to patients and providers alike. Tamoxifen, a well-established selective estrogen receptor modulator, offers a novel and cost-effective approach to accelerate testosterone recovery in men with secondary hypogonadism. This project addresses a critical gap in global cancer care by evaluating Tamoxifen as a viable solution for reducing the burden of delayed testosterone recovery and its associated side effects, particularly in resource-limited settings.

Phase 2
Waitlist Available

University Health Network - Princess Margaret Cancer Center

Image of Albert Einstein College of Medicine in The Bronx, United States.

Vaginal Estradiol vs Moisturizer for Menopause in Women with HIV

40 - 70
Female
The Bronx, NY

This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.

Phase 4
Waitlist Available

Albert Einstein College of Medicine

Kerry J Murphy, MD

Image of University of Michigan Rogel Cancer Center in Ann Arbor, United States.

Urine Screening + MRI for Prostate Cancer

50 - 75
Male
Ann Arbor, MI

This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.

Waitlist Available
Has No Placebo

University of Michigan Rogel Cancer Center

Udit Singhal, MD

Have you considered Estring clinical trials?

We made a collection of clinical trials featuring Estring, we think they might fit your search criteria.
Go to Trials
Image of Resound Research for Reproductive Health, a project of the Tides Center in San Francisco, United States.

"Vasectomy: Right for Me?" Decision Aid for Birth Control

21 - 55
Male
San Francisco, CA

The goal of this trial is to learn if a web-based decision aid designed to provide evidence-based information about vasectomy and other birth control options helps improve users' decision-making about birth control. The main questions it aims to answer are: * Do people who use the decision aid have better knowledge about vasectomy? * Do people who use the decision aid have lower conflict with their decision? Participants will: * Use the decision aid (if they are assigned to the intervention arm). * Answer survey questions about their knowledge, decision-making, interest in vasectomy, and healthcare navigation experiences.

Waitlist Available
Has No Placebo

Resound Research for Reproductive Health, a project of the Tides Center (+1 Sites)

Sonya Borrero, MD, MS

Image of University of Texas in Houston, United States.

vNOTES Hysterectomy for Pelvic Prolapse

18+
Female
Houston, TX

As the adoption of Vaginal natural orifice transluminal endoscopic surgery (vNOTES) expands, attention is shifting from feasibility studies to the refinement of surgical steps that optimize long-term pelvic health. One technical distinction between vNOTES hysterectomy and conventional laparoscopic or robotic hysterectomy is the routine early transection of the uterosacral ligaments as the approach is caudal-cephalic. These ligaments are not merely anatomic landmarks-they are the primary apical support structures of the vagina, anchoring the vaginal cuff to the sacrum and providing resistance against downward displacement. Disruption of this support can predispose patients to apical vaginal prolapse, a condition that significantly affects quality of life and may require complex reconstructive surgery. Uterosacral ligament suspension (USLS) is a well-established, effective method of restoring apical support at the time of hysterectomy. Incorporating uterosacral suspension into vNOTES hysterectomy is a logical evolution toward ensuring that minimally invasive innovation does not come at the expense of long-term pelvic health. By adapting and standardizing this reconstructive step for vNOTES, surgeons can maintain apical support, reduce future prolapse risk, and uphold the same quality benchmarks established in laparoscopic and vaginal surgery. OBJECTIVE AND HYPOTHESIS: This study aims to present a practical, reproducible technique for performing USLS in the vNOTES setting and to evaluate its potential immediate benefits, possible complication rates, and additional operative time compared with vNOTES hysterectomy without USLS. In doing so, we seek to demonstrate that preventive pelvic support can be seamlessly integrated without compromising the efficiency or advantages of the transvaginal endoscopic approach.

Waitlist Available
Paid Trial

University of Texas

Image of Translational Physiology Laboratory within the Food Science Clinical Research Laboratory in Fort Collins, United States.

Mitoquinone for Postmenopausal Brain Health

18+
Female
Fort Collins, CO

The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are: Does MitoQ improve cerebrovascular function in postmenopausal women? If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries? Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function. Participants will: Take MitoQ (20 mg/day) or a placebo every day for 3 months Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point Keep track of symptoms and events during their treatment period to report to the study team

Waitlist Available
Dietary Supplement

Translational Physiology Laboratory within the Food Science Clinical Research Laboratory

Have you considered Estring clinical trials?

We made a collection of clinical trials featuring Estring, we think they might fit your search criteria.
Go to Trials
Image of M D Anderson Cancer Center in Houston, United States.

Decision Support Tool for Prostate Cancer

18+
Male
Houston, TX

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.

Waitlist Available
Has No Placebo

M D Anderson Cancer Center

Debanjan Pain

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Recruiting
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Have you considered Estring clinical trials?

We made a collection of clinical trials featuring Estring, we think they might fit your search criteria.
Go to Trials